

Graeme Sills

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4018818/graeme-sills-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

5
papers

106
citations

4
h-index

5
g-index

5
ext. papers

169
ext. citations

17.1
avg, IF

0.94
L-index

#	Paper	IF	Citations
5	The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. <i>Lancet, The</i> , 2021 , 397, 1375-1386	4.0	37
4	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 1028-1036	6.1	34
3	The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. <i>Lancet, The</i> , 2021 , 397, 1363-1374	4.0	29
2	Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II). <i>BMJ Open</i> , 2020 , 10, e040635	3	4
1	Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.. <i>Health Technology Assessment</i> , 2021 , 25, 1-134	4.4	2